Pharmaceutical Technology

MARCH 24, 2023

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. However, it has taken over six years for Amjevita to launch, after first being FDA-approved in 2016. Many other biosimilars have also been FDA-approved since 2016.

Competition 59

Competition Marketing FDA Physicians 59

Clarify Health

MARCH 1, 2023

1] In a separate, controlled study, 80 percent of primary care physicians receiving micro-incentives referred patients to higher-value specialists they had never used before — representing a significant reduction in the total cost of care. Healthcare (2016), [link] [2] Parikh, R. million on orthopedic MS-DRGs.[1]

Physicians 52

Physicians Prescription Medicine Healthcare 52

pharmaphorum

DECEMBER 2, 2022

Enrolling for clinical trials has become more challenging in recent years, with trial competition, increasingly complex protocols, and precision medicine targeting more niche patient populations. Using real-time data to track the trends at the physician level can be critical for successful enrolment in these scenarios. Getz, Kenneth.

Competition 96

Competition Leads Patients Electronics 96

Clarivate

MAY 24, 2023

An earlier Sarepta DMD drug, the antisense oligonucleotide (ASO) treatment EXONDYS 51, was priced at $300,000 a year for the average patient when it won FDA approval in 2016. With 11 gene therapies already approved payers are bracing for impact as Cortellis Competitive Intelligence data identifies another 30 in late-stage pipelines.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

PM360

MARCH 24, 2023

Starting with Vermont in 2016, more than half of the U.S. When the states realize that price discovery and competition already exist and that the real mark-ups take place at the pharmacy benefit manager (PBM) and retail pharmacy levels, manufacturers will have to comply and report.

Manufacturing 96

Manufacturing Retail Management Marketing 96

PharmaKinnex

AUGUST 23, 2022

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. Let’s dive into the current state of the pharma industry and learn more about what your team can do to stay ahead of the curve and the competition. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

Pharma 52

Pharma Sales Sales Strategy Marketing 52

pharmaphorum

JUNE 29, 2022

Lockdowns are no longer; but the more hybrid model of physician and patient engagement is here to stay; the challenge for launching companies is how to optimise engagement impact and patient opportunity within them. Launches, therefore, were happening. But were they fulfilling their commercial potential?

Doctors 59

Doctors Medicine Marketing Sales 59